Grufity logo
Grufity logo
KZR

KZR - Kezar Life Sciences Inc Stock Price, Fair Value and News

$7.29 
Market Closed as of 11 May 2026, 04:00 pm ET

Price Targets

KZR Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

KZR Price Action

Last 7 days

-0.5%

Last 30 days

-1.2%

Last 90 days

19.1%

Trailing 12 Months

76.9%

KZR RSI Chart

KZR Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

KZR Valuation

Market Cap

53.8M

Price/Earnings (Trailing)

-1.19

Price/Sales (Trailing)

7.68

EV/EBITDA

0.23

Price/Free Cashflow

-1.28

KZR Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

KZR Fundamentals

KZR Revenue

Revenue (TTM)

7.0M

KZR Earnings

Earnings (TTM)

-45.2M

Earnings Growth (Yr)

65.23%

Earnings Growth (Qtr)

60.43%

KZR Profitability

EBT Margin

-800.47%

Return on Equity

-69.34%

Return on Assets

-66.52%

Free Cashflow Yield

-78.19%

KZR Investor Care

Shares Dilution (1Y)

0.94%

Diluted EPS (TTM)

-6.17

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
2025----
2024----
2023---7.0M
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Kezar Life Sciences Inc

KZR
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
 CEO
 WEBSITEkezarlifesciences.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES84

Kezar Life Sciences Inc Frequently Asked Questions

KZR is the stock ticker symbol of Kezar Life Sciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Mon May 11 2026, market cap of Kezar Life Sciences Inc is 53.76 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Mon May 11 2026, KZR's PE ratio (Price to Earnings) is -1.19 and Price to Sales (PS) ratio is 7.68. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. KZR PE ratio will change depending on the future growth rate expectations of investors.